Rhumbline Advisers Veracyte, Inc. Transaction History

Rhumbline Advisers

  • $109 Billion
  • Q3 2024

A detailed history of Rhumbline Advisers transactions in Veracyte, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 122,649 shares of VCYT stock, worth $5.25 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
122,649
Previous 128,774 4.76%
Holding current value
$5.25 Million
Previous $2.79 Million 49.57%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024
SELL
$21.0 - $35.25 $128,625 - $215,906
-6,125 Reduced 4.76%
122,649 $4.17 Million
Q2 2024

Aug 01, 2024
BUY
$18.86 - $23.55 $152,690 - $190,660
8,096 Added 6.71%
128,774 $2.79 Million
Q1 2024

May 09, 2024
BUY
$21.0 - $29.1 $57,666 - $79,908
2,746 Added 2.33%
120,678 $2.67 Million
Q4 2023

Feb 08, 2024
SELL
$19.72 - $28.68 $8,814 - $12,819
-447 Reduced 0.38%
117,932 $3.24 Million
Q3 2023

Nov 09, 2023
BUY
$22.33 - $29.92 $40,930 - $54,843
1,833 Added 1.57%
118,379 $2.64 Million
Q2 2023

Aug 08, 2023
SELL
$20.96 - $26.99 $6,686 - $8,609
-319 Reduced 0.27%
116,546 $2.97 Million
Q1 2023

May 11, 2023
BUY
$20.58 - $27.89 $39,122 - $53,018
1,901 Added 1.65%
116,865 $2.61 Million
Q4 2022

Feb 14, 2023
BUY
$15.31 - $29.94 $53,707 - $105,029
3,508 Added 3.15%
114,964 $2.73 Million
Q3 2022

Nov 10, 2022
BUY
$16.58 - $27.9 $101,950 - $171,557
6,149 Added 5.84%
111,456 $1.85 Million
Q2 2022

Aug 11, 2022
BUY
$15.45 - $29.52 $252,391 - $482,238
16,336 Added 18.36%
105,307 $2.1 Million
Q1 2022

May 12, 2022
SELL
$21.94 - $42.51 $164,769 - $319,250
-7,510 Reduced 7.78%
88,971 $2.45 Million
Q4 2021

Feb 10, 2022
SELL
$36.09 - $53.79 $41,467 - $61,804
-1,149 Reduced 1.18%
96,481 $3.98 Million
Q3 2021

Nov 12, 2021
BUY
$35.62 - $52.97 $69,743 - $103,715
1,958 Added 2.05%
97,630 $4.54 Million
Q2 2021

Aug 05, 2021
BUY
$32.94 - $56.62 $856,044 - $1.47 Million
25,988 Added 37.29%
95,672 $3.83 Million
Q1 2021

May 06, 2021
SELL
$44.47 - $81.38 $20,144 - $36,865
-453 Reduced 0.65%
69,684 $3.75 Million
Q4 2020

Feb 10, 2021
BUY
$32.49 - $61.88 $140,649 - $267,878
4,329 Added 6.58%
70,137 $3.43 Million
Q3 2020

Nov 12, 2020
SELL
$26.73 - $35.67 $170,884 - $228,038
-6,393 Reduced 8.85%
65,808 $2.14 Million
Q2 2020

Aug 13, 2020
BUY
$19.49 - $28.11 $147,851 - $213,242
7,586 Added 11.74%
72,201 $1.87 Million
Q1 2020

May 06, 2020
BUY
$16.13 - $30.17 $18,339 - $34,303
1,137 Added 1.79%
64,615 $1.57 Million
Q4 2019

Feb 05, 2020
BUY
$20.78 - $29.99 $90,413 - $130,486
4,351 Added 7.36%
63,478 $1.77 Million
Q3 2019

Oct 23, 2019
BUY
$23.87 - $30.93 $8,187 - $10,608
343 Added 0.58%
59,127 $1.42 Million
Q2 2019

Aug 14, 2019
BUY
$22.1 - $28.56 $510,355 - $659,536
23,093 Added 64.7%
58,784 $1.68 Million
Q1 2019

May 01, 2019
BUY
$12.0 - $25.76 $2,184 - $4,688
182 Added 0.51%
35,691 $893,000
Q4 2018

Jan 31, 2019
BUY
$9.15 - $14.85 $125,053 - $202,954
13,667 Added 62.57%
35,509 $447,000
Q3 2018

Nov 07, 2018
SELL
$9.55 - $12.64 $3,581 - $4,740
-375 Reduced 1.69%
21,842 $209,000
Q2 2018

Aug 06, 2018
BUY
$5.39 - $9.66 $9,459 - $16,953
1,755 Added 8.58%
22,217 $208,000
Q1 2018

May 02, 2018
BUY
$5.44 - $6.97 $516 - $662
95 Added 0.47%
20,462 $114,000
Q4 2017

Feb 09, 2018
SELL
$6.05 - $9.37 $28,749 - $44,526
-4,752 Reduced 18.92%
20,367 $133,000
Q3 2017

Nov 06, 2017
BUY
$7.81 - $8.77 $196,179 - $220,293
25,119
25,119 $220,000

Others Institutions Holding VCYT

# of Institutions
308
Shares Held
81.8M
Call Options Held
134K
Put Options Held
13.3K
View Full List

About VERACYTE, INC.

VCYT Quotes by TradingView
  • Ticker VCYT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,575,904
  • Market Cap $3.07B
  • Description
  • Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...
More about VCYT
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email